Literature DB >> 19260820

Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin.

James Price, Stephen Atkinson, Martin Llewelyn, John Paul.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19260820     DOI： 10.1086/597359

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  21 in total

1.  An association between bacterial genotype combined with a high-vancomycin minimum inhibitory concentration and risk of endocarditis in methicillin-resistant Staphylococcus aureus bloodstream infection.

Authors:  Clare E Miller; Rahul Batra; Ben S Cooper; Amita K Patel; John Klein; Jonathan A Otter; Theodore Kypraios; Gary L French; Olga Tosas; Jonathan D Edgeworth
Journal:  Clin Infect Dis       Date:  2011-12-20       Impact factor: 9.079

2.  Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia.

Authors:  Sanjiv M Baxi; Angelo Clemenzi-Allen; Alice Gahbauer; Daniel Deck; Brandon Imp; Eric Vittinghoff; Henry F Chambers; Sarah Doernberg
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

3.  Effect of reduced vancomycin susceptibility on clinical and economic outcomes in Staphylococcus aureus bacteremia.

Authors:  Jennifer H Han; Kara B Mascitti; Paul H Edelstein; Warren B Bilker; Ebbing Lautenbach
Journal:  Antimicrob Agents Chemother       Date:  2012-07-23       Impact factor: 5.191

Review 4.  Mechanisms of vancomycin resistance in Staphylococcus aureus.

Authors:  Susana Gardete; Alexander Tomasz
Journal:  J Clin Invest       Date:  2014-07-01       Impact factor: 14.808

Review 5.  Future challenges and treatment of Staphylococcus aureus bacteremia with emphasis on MRSA.

Authors:  Rasmus V Rasmussen; Vance G Fowler; Robert Skov; Niels E Bruun
Journal:  Future Microbiol       Date:  2011-01       Impact factor: 3.165

6.  Factors influencing time to vancomycin-induced clearance of nonendocarditis methicillin-resistant Staphylococcus aureus bacteremia: role of platelet microbicidal protein killing and agr genotypes.

Authors:  Pamela A Moise; Alan Forrest; Arnold S Bayer; Yan Q Xiong; Michael R Yeaman; George Sakoulas
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

7.  Clinical and Microbiological Determinants of Outcome in Staphylococcus aureus Bacteraemia.

Authors:  James Price; Gillian Baker; Ian Heath; Karen Walker-Bone; Marc Cubbon; Sally Curtis; Mark C Enright; Jodi Lindsay; John Paul; Martin Llewelyn
Journal:  Int J Microbiol       Date:  2010-03-16

8.  Comparison of In-vitro Activities of Linezolid and Vancomycin against Staphylococcus aureus Isolated from A Tertiary Care Hospital.

Authors:  Sachin Kishore; Deepika Verma; Me Siddique
Journal:  J Clin Diagn Res       Date:  2014-05-15

9.  Impact of Vancomycin MIC on Clinical Outcomes of Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin at an Institution with Suppressed MIC Reporting.

Authors:  Shaili Adani; Tanaya Bhowmick; Melvin P Weinstein; Navaneeth Narayanan
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

10.  Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia.

Authors:  Natasha E Holmes; John D Turnidge; Wendy J Munckhof; J Owen Robinson; Tony M Korman; Matthew V N O'Sullivan; Tara L Anderson; Sally A Roberts; Sanchia J C Warren; Wei Gao; Benjamin P Howden; Paul D R Johnson
Journal:  Antimicrob Agents Chemother       Date:  2013-01-18       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.